The planned MADIT‐CRT trial is designed to determine if CRT‐D will reduce the risk of mortality and HF events by approximately 25% in subjects with ischemic (NYHA class I‐II) and non‐ischemic (NYHA class II) cardiomyopathy, left ventricular dysfunction (EF ≤ 0.30), and prolonged intraventricular con...
Research Assistant
AI chat, annotations, notes & similar papers
No comments yet
Be the first to share your thoughts!